Cost-Effectiveness of Meningococcal Quadrivalent Conjugate Vaccination Campaign among Men Who Have Sex With Men in New York City
Background: To control an outbreak of invasive meningococcal disease (IMD) among men who have sex with men (MSM) in New York City (NYC), the NYC Department of Health and Mental Hygiene (DOHMH) recommended vaccination of all HIV-positive MSM and HIV-negative MSM with “intimate contact with a man met through an online Web site, digital application or at a bar or party”
Methods: We used a decision analytic model to estimate the effectiveness and cost-effectiveness of the meningococcal quadrivalent conjugate vaccination campaign as compared to no vaccination. We estimated approximately 60,000 NYC MSM to be targeted through DOHMH recommendations based on NYC Community Health Survey and NYC HIV/AIDS surveillance registry data. Model inputs, including IMD incidence of 20.5 per 100,000 HIV-positive MSM (42% fatal) and 7.6 per 100,000 HIV-negative MSM (20% fatal), were from DOHMH data and published sources. Outcome measures included costs (2012 US dollars), IMD cases averted, IMD deaths averted, quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratios ($/QALY). Sensitivity analyses were performed on key inputs including herd immunity (base case 20% protection in all unvaccinated MSM).
Results: Compared to no vaccination, the targeted vaccination campaign averted an estimated 2.7 IMD cases (modeled range 0.9-6.0) and 1.0 IMD deaths (modeled range 0.2-2.5) and had an incremental cost-effectiveness ratio of $60,100/QALY. At a cost-effectiveness threshold of $100,000/QALY, vaccination remained cost-effective at an IMD incidence as low as 10 per 100,000 persons or at a case fatality rate greater than 13% in all MSM. At a societal willingness to pay consistent with adopted meningococcal vaccination guidelines for adolescents ($230,000/QALY), vaccination was cost-effective at an IMD incidence as low as 5 per 100,000 persons. Results were sensitive to assumptions regarding herd immunity (Figure).
Conclusion: Vaccination during a community-wide IMD outbreak among MSM in NYC was projected to avert IMD cases and deaths and had an incremental cost-effectiveness ratio less than $100,000/QALY. Cost-effectiveness was highly dependent on herd immunity.
M. S. Simon,
A. Geevarughese, None
B. Cutler, None
R. M. Gulick, None
J. R. Zucker, None
J. K. Varma, None
B. R. Schackman, None